Effects of long-term medical treatment with cimetidine and bethanechol in patients with esophagitis and Barrett's esophagus.
To evaluate long-term medical therapy in patients with Barrett's esophagus, six patients were studied before and after long-term therapy with cimetidine for a mean period of 11.7 months. Some patients also received bethanechol. All had severe symptoms of gastroesophageal reflux resistant to intensive antacid therapy, specialized columnar epithelium by biopsy, and endoscopic evidence of severe inflammation. Esophageal manometry documented a hypotensive lower esophageal sphincter in three patients and low peristaltic amplitude in the distal esophagus in four. Treatment was begun with cimetidine, 300 mg orally four times daily. If symptoms did not totally abate, bethanechol, 25 mg orally four times daily, was added. Cimetidine completely relieved or dramatically reduced symptoms in all patients. Adding bethanechol produced further symptomatic improvement in three of four patients. After initial dilatation in the two patients with strictures, there was no recurrence. Endoscopic evidence of inflammation resolved completely in four patients and was markedly improved in two. Treatment with both drugs was well tolerated by all patients. The abnormally placed squamo-columnar junction did not regress during follow-up.
D000328:Adult; D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use*; D004935:Esophageal Diseases / Q000188:drug therapy*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006356:Heartburn / Q000209:etiology; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D011446:Prospective Studies
D001626:Bethanechol Compounds; D018723:Bethanechol; D002927:Cimetidine